nodes	percent_of_prediction	percent_of_DWPC	metapath
Vidarabine—Glucosamine—TNF—ankylosing spondylitis	0.0282	1	CrCbGaD
Vidarabine—Intracranial pressure increased—Prednisolone—ankylosing spondylitis	0.0252	0.0259	CcSEcCtD
Vidarabine—Intracranial pressure increased—Triamcinolone—ankylosing spondylitis	0.0232	0.0239	CcSEcCtD
Vidarabine—Intracranial pressure increased—Methylprednisolone—ankylosing spondylitis	0.0231	0.0238	CcSEcCtD
Vidarabine—Intracranial pressure increased—Betamethasone—ankylosing spondylitis	0.021	0.0216	CcSEcCtD
Vidarabine—Intracranial pressure increased—Dexamethasone—ankylosing spondylitis	0.021	0.0216	CcSEcCtD
Vidarabine—Taste metallic—Methotrexate—ankylosing spondylitis	0.0201	0.0207	CcSEcCtD
Vidarabine—Intracranial pressure increased—Prednisone—ankylosing spondylitis	0.0183	0.0188	CcSEcCtD
Vidarabine—Tingling sensation—Methylprednisolone—ankylosing spondylitis	0.012	0.0124	CcSEcCtD
Vidarabine—Tingling sensation—Betamethasone—ankylosing spondylitis	0.0109	0.0112	CcSEcCtD
Vidarabine—Tingling sensation—Dexamethasone—ankylosing spondylitis	0.0109	0.0112	CcSEcCtD
Vidarabine—Burning sensation—Methotrexate—ankylosing spondylitis	0.0092	0.00947	CcSEcCtD
Vidarabine—Apnoea—Methotrexate—ankylosing spondylitis	0.00754	0.00776	CcSEcCtD
Vidarabine—Affect lability—Prednisolone—ankylosing spondylitis	0.00752	0.00774	CcSEcCtD
Vidarabine—Cardiac arrest—Prednisolone—ankylosing spondylitis	0.00727	0.00748	CcSEcCtD
Vidarabine—Mood swings—Prednisolone—ankylosing spondylitis	0.00724	0.00745	CcSEcCtD
Vidarabine—Cardiac failure—Methylprednisolone—ankylosing spondylitis	0.00719	0.00739	CcSEcCtD
Vidarabine—Affect lability—Triamcinolone—ankylosing spondylitis	0.00692	0.00712	CcSEcCtD
Vidarabine—Affect lability—Methylprednisolone—ankylosing spondylitis	0.0069	0.0071	CcSEcCtD
Vidarabine—Cardiac arrest—Triamcinolone—ankylosing spondylitis	0.00668	0.00688	CcSEcCtD
Vidarabine—Cardiac arrest—Methylprednisolone—ankylosing spondylitis	0.00667	0.00686	CcSEcCtD
Vidarabine—Mood swings—Triamcinolone—ankylosing spondylitis	0.00666	0.00685	CcSEcCtD
Vidarabine—Mood swings—Methylprednisolone—ankylosing spondylitis	0.00664	0.00684	CcSEcCtD
Vidarabine—Cardiac failure—Betamethasone—ankylosing spondylitis	0.00653	0.00672	CcSEcCtD
Vidarabine—Cardiac failure—Dexamethasone—ankylosing spondylitis	0.00653	0.00672	CcSEcCtD
Vidarabine—Respiratory failure—Methotrexate—ankylosing spondylitis	0.00651	0.0067	CcSEcCtD
Vidarabine—Affect lability—Dexamethasone—ankylosing spondylitis	0.00628	0.00646	CcSEcCtD
Vidarabine—Affect lability—Betamethasone—ankylosing spondylitis	0.00628	0.00646	CcSEcCtD
Vidarabine—Cardiac arrest—Dexamethasone—ankylosing spondylitis	0.00606	0.00624	CcSEcCtD
Vidarabine—Cardiac arrest—Betamethasone—ankylosing spondylitis	0.00606	0.00624	CcSEcCtD
Vidarabine—Mood swings—Betamethasone—ankylosing spondylitis	0.00604	0.00622	CcSEcCtD
Vidarabine—Mood swings—Dexamethasone—ankylosing spondylitis	0.00604	0.00622	CcSEcCtD
Vidarabine—Bronchospasm—Methylprednisolone—ankylosing spondylitis	0.00596	0.00613	CcSEcCtD
Vidarabine—Acute coronary syndrome—Prednisolone—ankylosing spondylitis	0.00581	0.00597	CcSEcCtD
Vidarabine—Myocardial infarction—Prednisolone—ankylosing spondylitis	0.00577	0.00594	CcSEcCtD
Vidarabine—Cardiac failure—Prednisone—ankylosing spondylitis	0.00569	0.00586	CcSEcCtD
Vidarabine—Affect lability—Prednisone—ankylosing spondylitis	0.00547	0.00562	CcSEcCtD
Vidarabine—Bradycardia—Prednisolone—ankylosing spondylitis	0.00538	0.00554	CcSEcCtD
Vidarabine—Acute coronary syndrome—Triamcinolone—ankylosing spondylitis	0.00534	0.00549	CcSEcCtD
Vidarabine—Acute coronary syndrome—Methylprednisolone—ankylosing spondylitis	0.00533	0.00548	CcSEcCtD
Vidarabine—Myocardial infarction—Triamcinolone—ankylosing spondylitis	0.00531	0.00546	CcSEcCtD
Vidarabine—Myocardial infarction—Methylprednisolone—ankylosing spondylitis	0.0053	0.00545	CcSEcCtD
Vidarabine—Cardiac arrest—Prednisone—ankylosing spondylitis	0.00528	0.00543	CcSEcCtD
Vidarabine—Mood swings—Prednisone—ankylosing spondylitis	0.00526	0.00541	CcSEcCtD
Vidarabine—Sweating—Methylprednisolone—ankylosing spondylitis	0.00518	0.00533	CcSEcCtD
Vidarabine—Bradycardia—Triamcinolone—ankylosing spondylitis	0.00495	0.00509	CcSEcCtD
Vidarabine—Bradycardia—Methylprednisolone—ankylosing spondylitis	0.00494	0.00508	CcSEcCtD
Vidarabine—Acute coronary syndrome—Betamethasone—ankylosing spondylitis	0.00484	0.00499	CcSEcCtD
Vidarabine—Acute coronary syndrome—Dexamethasone—ankylosing spondylitis	0.00484	0.00499	CcSEcCtD
Vidarabine—Myocardial infarction—Betamethasone—ankylosing spondylitis	0.00482	0.00496	CcSEcCtD
Vidarabine—Myocardial infarction—Dexamethasone—ankylosing spondylitis	0.00482	0.00496	CcSEcCtD
Vidarabine—Cerebrovascular accident—Methotrexate—ankylosing spondylitis	0.00474	0.00487	CcSEcCtD
Vidarabine—Arrhythmia—Prednisolone—ankylosing spondylitis	0.00472	0.00486	CcSEcCtD
Vidarabine—Cardiac disorder—Methylprednisolone—ankylosing spondylitis	0.0045	0.00463	CcSEcCtD
Vidarabine—Bradycardia—Dexamethasone—ankylosing spondylitis	0.00449	0.00462	CcSEcCtD
Vidarabine—Bradycardia—Betamethasone—ankylosing spondylitis	0.00449	0.00462	CcSEcCtD
Vidarabine—Mood swings—Methotrexate—ankylosing spondylitis	0.0044	0.00452	CcSEcCtD
Vidarabine—Mediastinal disorder—Methylprednisolone—ankylosing spondylitis	0.00437	0.0045	CcSEcCtD
Vidarabine—Arrhythmia—Triamcinolone—ankylosing spondylitis	0.00434	0.00447	CcSEcCtD
Vidarabine—Vision blurred—Prednisolone—ankylosing spondylitis	0.00434	0.00446	CcSEcCtD
Vidarabine—Arrhythmia—Methylprednisolone—ankylosing spondylitis	0.00433	0.00446	CcSEcCtD
Vidarabine—Acute coronary syndrome—Prednisone—ankylosing spondylitis	0.00422	0.00434	CcSEcCtD
Vidarabine—Angioedema—Prednisolone—ankylosing spondylitis	0.00421	0.00433	CcSEcCtD
Vidarabine—Myocardial infarction—Prednisone—ankylosing spondylitis	0.00419	0.00432	CcSEcCtD
Vidarabine—Dysgeusia—Triamcinolone—ankylosing spondylitis	0.00414	0.00427	CcSEcCtD
Vidarabine—Syncope—Prednisolone—ankylosing spondylitis	0.00413	0.00425	CcSEcCtD
Vidarabine—Back pain—Triamcinolone—ankylosing spondylitis	0.00409	0.00421	CcSEcCtD
Vidarabine—Loss of consciousness—Prednisolone—ankylosing spondylitis	0.00405	0.00416	CcSEcCtD
Vidarabine—Convulsion—Prednisolone—ankylosing spondylitis	0.00399	0.0041	CcSEcCtD
Vidarabine—Hypertension—Prednisolone—ankylosing spondylitis	0.00397	0.00409	CcSEcCtD
Vidarabine—Arrhythmia—Dexamethasone—ankylosing spondylitis	0.00394	0.00406	CcSEcCtD
Vidarabine—Arrhythmia—Betamethasone—ankylosing spondylitis	0.00394	0.00406	CcSEcCtD
Vidarabine—Bradycardia—Prednisone—ankylosing spondylitis	0.00391	0.00402	CcSEcCtD
Vidarabine—Discomfort—Prednisolone—ankylosing spondylitis	0.00387	0.00398	CcSEcCtD
Vidarabine—Angioedema—Triamcinolone—ankylosing spondylitis	0.00387	0.00398	CcSEcCtD
Vidarabine—Angioedema—Methylprednisolone—ankylosing spondylitis	0.00386	0.00397	CcSEcCtD
Vidarabine—Abdominal discomfort—Methotrexate—ankylosing spondylitis	0.00385	0.00396	CcSEcCtD
Vidarabine—Syncope—Triamcinolone—ankylosing spondylitis	0.0038	0.00391	CcSEcCtD
Vidarabine—Syncope—Methylprednisolone—ankylosing spondylitis	0.00379	0.0039	CcSEcCtD
Vidarabine—Anaphylactic shock—Prednisolone—ankylosing spondylitis	0.00376	0.00387	CcSEcCtD
Vidarabine—Loss of consciousness—Triamcinolone—ankylosing spondylitis	0.00372	0.00383	CcSEcCtD
Vidarabine—Loss of consciousness—Methylprednisolone—ankylosing spondylitis	0.00371	0.00382	CcSEcCtD
Vidarabine—Shock—Prednisolone—ankylosing spondylitis	0.0037	0.0038	CcSEcCtD
Vidarabine—Cough—Triamcinolone—ankylosing spondylitis	0.00369	0.0038	CcSEcCtD
Vidarabine—Convulsion—Triamcinolone—ankylosing spondylitis	0.00367	0.00377	CcSEcCtD
Vidarabine—Tachycardia—Prednisolone—ankylosing spondylitis	0.00367	0.00377	CcSEcCtD
Vidarabine—Convulsion—Methylprednisolone—ankylosing spondylitis	0.00366	0.00377	CcSEcCtD
Vidarabine—Hypertension—Triamcinolone—ankylosing spondylitis	0.00365	0.00376	CcSEcCtD
Vidarabine—Hypertension—Methylprednisolone—ankylosing spondylitis	0.00365	0.00375	CcSEcCtD
Vidarabine—Hyperhidrosis—Prednisolone—ankylosing spondylitis	0.00363	0.00374	CcSEcCtD
Vidarabine—Anxiety—Methylprednisolone—ankylosing spondylitis	0.00358	0.00369	CcSEcCtD
Vidarabine—Drowsiness—Methotrexate—ankylosing spondylitis	0.00358	0.00368	CcSEcCtD
Vidarabine—Flushing—Prednisone—ankylosing spondylitis	0.00357	0.00367	CcSEcCtD
Vidarabine—Discomfort—Triamcinolone—ankylosing spondylitis	0.00356	0.00366	CcSEcCtD
Vidarabine—Discomfort—Methylprednisolone—ankylosing spondylitis	0.00355	0.00366	CcSEcCtD
Vidarabine—Dry mouth—Triamcinolone—ankylosing spondylitis	0.00352	0.00363	CcSEcCtD
Vidarabine—Angioedema—Betamethasone—ankylosing spondylitis	0.00351	0.00361	CcSEcCtD
Vidarabine—Angioedema—Dexamethasone—ankylosing spondylitis	0.00351	0.00361	CcSEcCtD
Vidarabine—Anaphylactic shock—Triamcinolone—ankylosing spondylitis	0.00345	0.00355	CcSEcCtD
Vidarabine—Anaphylactic shock—Methylprednisolone—ankylosing spondylitis	0.00345	0.00355	CcSEcCtD
Vidarabine—Syncope—Betamethasone—ankylosing spondylitis	0.00344	0.00354	CcSEcCtD
Vidarabine—Syncope—Dexamethasone—ankylosing spondylitis	0.00344	0.00354	CcSEcCtD
Vidarabine—Arrhythmia—Prednisone—ankylosing spondylitis	0.00343	0.00353	CcSEcCtD
Vidarabine—Sweating—Methotrexate—ankylosing spondylitis	0.00343	0.00353	CcSEcCtD
Vidarabine—Shock—Triamcinolone—ankylosing spondylitis	0.0034	0.0035	CcSEcCtD
Vidarabine—Shock—Methylprednisolone—ankylosing spondylitis	0.00339	0.00349	CcSEcCtD
Vidarabine—Loss of consciousness—Dexamethasone—ankylosing spondylitis	0.00338	0.00347	CcSEcCtD
Vidarabine—Loss of consciousness—Betamethasone—ankylosing spondylitis	0.00338	0.00347	CcSEcCtD
Vidarabine—Paraesthesia—Prednisolone—ankylosing spondylitis	0.00337	0.00347	CcSEcCtD
Vidarabine—Tachycardia—Triamcinolone—ankylosing spondylitis	0.00337	0.00347	CcSEcCtD
Vidarabine—Tachycardia—Methylprednisolone—ankylosing spondylitis	0.00336	0.00346	CcSEcCtD
Vidarabine—Hyperhidrosis—Triamcinolone—ankylosing spondylitis	0.00334	0.00344	CcSEcCtD
Vidarabine—Hyperhidrosis—Methylprednisolone—ankylosing spondylitis	0.00333	0.00343	CcSEcCtD
Vidarabine—Convulsion—Betamethasone—ankylosing spondylitis	0.00333	0.00342	CcSEcCtD
Vidarabine—Convulsion—Dexamethasone—ankylosing spondylitis	0.00333	0.00342	CcSEcCtD
Vidarabine—Hypertension—Dexamethasone—ankylosing spondylitis	0.00332	0.00341	CcSEcCtD
Vidarabine—Hypertension—Betamethasone—ankylosing spondylitis	0.00332	0.00341	CcSEcCtD
Vidarabine—Anxiety—Betamethasone—ankylosing spondylitis	0.00326	0.00335	CcSEcCtD
Vidarabine—Anxiety—Dexamethasone—ankylosing spondylitis	0.00326	0.00335	CcSEcCtD
Vidarabine—Discomfort—Dexamethasone—ankylosing spondylitis	0.00323	0.00332	CcSEcCtD
Vidarabine—Discomfort—Betamethasone—ankylosing spondylitis	0.00323	0.00332	CcSEcCtD
Vidarabine—Hypotension—Methylprednisolone—ankylosing spondylitis	0.00322	0.00331	CcSEcCtD
Vidarabine—Pain—Prednisolone—ankylosing spondylitis	0.00321	0.00331	CcSEcCtD
Vidarabine—Vision blurred—Prednisone—ankylosing spondylitis	0.00315	0.00324	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Triamcinolone—ankylosing spondylitis	0.00315	0.00324	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Methylprednisolone—ankylosing spondylitis	0.00314	0.00323	CcSEcCtD
Vidarabine—Anaphylactic shock—Betamethasone—ankylosing spondylitis	0.00313	0.00323	CcSEcCtD
Vidarabine—Anaphylactic shock—Dexamethasone—ankylosing spondylitis	0.00313	0.00323	CcSEcCtD
Vidarabine—Paraesthesia—Triamcinolone—ankylosing spondylitis	0.0031	0.00319	CcSEcCtD
Vidarabine—Paraesthesia—Methylprednisolone—ankylosing spondylitis	0.00309	0.00318	CcSEcCtD
Vidarabine—Shock—Dexamethasone—ankylosing spondylitis	0.00308	0.00317	CcSEcCtD
Vidarabine—Shock—Betamethasone—ankylosing spondylitis	0.00308	0.00317	CcSEcCtD
Vidarabine—Dyspnoea—Triamcinolone—ankylosing spondylitis	0.00308	0.00317	CcSEcCtD
Vidarabine—Agitation—Prednisone—ankylosing spondylitis	0.00307	0.00316	CcSEcCtD
Vidarabine—Tachycardia—Betamethasone—ankylosing spondylitis	0.00306	0.00315	CcSEcCtD
Vidarabine—Tachycardia—Dexamethasone—ankylosing spondylitis	0.00306	0.00315	CcSEcCtD
Vidarabine—Angioedema—Prednisone—ankylosing spondylitis	0.00306	0.00314	CcSEcCtD
Vidarabine—Hyperhidrosis—Betamethasone—ankylosing spondylitis	0.00303	0.00312	CcSEcCtD
Vidarabine—Hyperhidrosis—Dexamethasone—ankylosing spondylitis	0.00303	0.00312	CcSEcCtD
Vidarabine—Syncope—Prednisone—ankylosing spondylitis	0.003	0.00309	CcSEcCtD
Vidarabine—Tinnitus—Methotrexate—ankylosing spondylitis	0.00299	0.00308	CcSEcCtD
Vidarabine—Urticaria—Prednisolone—ankylosing spondylitis	0.00298	0.00307	CcSEcCtD
Vidarabine—Cardiac disorder—Methotrexate—ankylosing spondylitis	0.00298	0.00307	CcSEcCtD
Vidarabine—Pain—Triamcinolone—ankylosing spondylitis	0.00295	0.00304	CcSEcCtD
Vidarabine—Loss of consciousness—Prednisone—ankylosing spondylitis	0.00294	0.00302	CcSEcCtD
Vidarabine—Hypotension—Betamethasone—ankylosing spondylitis	0.00293	0.00301	CcSEcCtD
Vidarabine—Hypotension—Dexamethasone—ankylosing spondylitis	0.00293	0.00301	CcSEcCtD
Vidarabine—Convulsion—Prednisone—ankylosing spondylitis	0.0029	0.00298	CcSEcCtD
Vidarabine—Mediastinal disorder—Methotrexate—ankylosing spondylitis	0.00289	0.00298	CcSEcCtD
Vidarabine—Hypertension—Prednisone—ankylosing spondylitis	0.00289	0.00297	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Betamethasone—ankylosing spondylitis	0.00286	0.00294	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Dexamethasone—ankylosing spondylitis	0.00286	0.00294	CcSEcCtD
Vidarabine—Anxiety—Prednisone—ankylosing spondylitis	0.00284	0.00292	CcSEcCtD
Vidarabine—Paraesthesia—Betamethasone—ankylosing spondylitis	0.00281	0.0029	CcSEcCtD
Vidarabine—Paraesthesia—Dexamethasone—ankylosing spondylitis	0.00281	0.0029	CcSEcCtD
Vidarabine—Discomfort—Prednisone—ankylosing spondylitis	0.00281	0.00289	CcSEcCtD
Vidarabine—Hypersensitivity—Prednisolone—ankylosing spondylitis	0.00277	0.00285	CcSEcCtD
Vidarabine—Urticaria—Triamcinolone—ankylosing spondylitis	0.00274	0.00282	CcSEcCtD
Vidarabine—Urticaria—Methylprednisolone—ankylosing spondylitis	0.00274	0.00282	CcSEcCtD
Vidarabine—Dysgeusia—Methotrexate—ankylosing spondylitis	0.00274	0.00282	CcSEcCtD
Vidarabine—Anaphylactic shock—Prednisone—ankylosing spondylitis	0.00273	0.00281	CcSEcCtD
Vidarabine—Back pain—Methotrexate—ankylosing spondylitis	0.0027	0.00278	CcSEcCtD
Vidarabine—Shock—Prednisone—ankylosing spondylitis	0.00269	0.00276	CcSEcCtD
Vidarabine—Pain—Dexamethasone—ankylosing spondylitis	0.00268	0.00276	CcSEcCtD
Vidarabine—Pain—Betamethasone—ankylosing spondylitis	0.00268	0.00276	CcSEcCtD
Vidarabine—Tachycardia—Prednisone—ankylosing spondylitis	0.00266	0.00274	CcSEcCtD
Vidarabine—Hyperhidrosis—Prednisone—ankylosing spondylitis	0.00264	0.00272	CcSEcCtD
Vidarabine—Vision blurred—Methotrexate—ankylosing spondylitis	0.00263	0.00271	CcSEcCtD
Vidarabine—Hypersensitivity—Triamcinolone—ankylosing spondylitis	0.00254	0.00262	CcSEcCtD
Vidarabine—Hypersensitivity—Methylprednisolone—ankylosing spondylitis	0.00254	0.00261	CcSEcCtD
Vidarabine—Urticaria—Dexamethasone—ankylosing spondylitis	0.00249	0.00256	CcSEcCtD
Vidarabine—Urticaria—Betamethasone—ankylosing spondylitis	0.00249	0.00256	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Prednisone—ankylosing spondylitis	0.00249	0.00256	CcSEcCtD
Vidarabine—Dizziness—Prednisolone—ankylosing spondylitis	0.00248	0.00256	CcSEcCtD
Vidarabine—Asthenia—Triamcinolone—ankylosing spondylitis	0.00248	0.00255	CcSEcCtD
Vidarabine—Asthenia—Methylprednisolone—ankylosing spondylitis	0.00247	0.00254	CcSEcCtD
Vidarabine—Paraesthesia—Prednisone—ankylosing spondylitis	0.00245	0.00252	CcSEcCtD
Vidarabine—Cough—Methotrexate—ankylosing spondylitis	0.00244	0.00251	CcSEcCtD
Vidarabine—Convulsion—Methotrexate—ankylosing spondylitis	0.00242	0.00249	CcSEcCtD
Vidarabine—Chest pain—Methotrexate—ankylosing spondylitis	0.00238	0.00245	CcSEcCtD
Vidarabine—Rash—Prednisolone—ankylosing spondylitis	0.00237	0.00244	CcSEcCtD
Vidarabine—Dermatitis—Prednisolone—ankylosing spondylitis	0.00237	0.00243	CcSEcCtD
Vidarabine—Headache—Prednisolone—ankylosing spondylitis	0.00235	0.00242	CcSEcCtD
Vidarabine—Discomfort—Methotrexate—ankylosing spondylitis	0.00235	0.00242	CcSEcCtD
Vidarabine—Dizziness—Triamcinolone—ankylosing spondylitis	0.00228	0.00235	CcSEcCtD
Vidarabine—Anaphylactic shock—Methotrexate—ankylosing spondylitis	0.00228	0.00235	CcSEcCtD
Vidarabine—Dizziness—Methylprednisolone—ankylosing spondylitis	0.00228	0.00235	CcSEcCtD
Vidarabine—Asthenia—Betamethasone—ankylosing spondylitis	0.00225	0.00231	CcSEcCtD
Vidarabine—Asthenia—Dexamethasone—ankylosing spondylitis	0.00225	0.00231	CcSEcCtD
Vidarabine—Nausea—Prednisolone—ankylosing spondylitis	0.00223	0.0023	CcSEcCtD
Vidarabine—Hyperhidrosis—Methotrexate—ankylosing spondylitis	0.00221	0.00227	CcSEcCtD
Vidarabine—Vomiting—Triamcinolone—ankylosing spondylitis	0.0022	0.00226	CcSEcCtD
Vidarabine—Vomiting—Methylprednisolone—ankylosing spondylitis	0.00219	0.00226	CcSEcCtD
Vidarabine—Rash—Triamcinolone—ankylosing spondylitis	0.00218	0.00224	CcSEcCtD
Vidarabine—Dermatitis—Triamcinolone—ankylosing spondylitis	0.00218	0.00224	CcSEcCtD
Vidarabine—Rash—Methylprednisolone—ankylosing spondylitis	0.00217	0.00224	CcSEcCtD
Vidarabine—Dermatitis—Methylprednisolone—ankylosing spondylitis	0.00217	0.00223	CcSEcCtD
Vidarabine—Urticaria—Prednisone—ankylosing spondylitis	0.00217	0.00223	CcSEcCtD
Vidarabine—Headache—Triamcinolone—ankylosing spondylitis	0.00216	0.00223	CcSEcCtD
Vidarabine—Headache—Methylprednisolone—ankylosing spondylitis	0.00216	0.00222	CcSEcCtD
Vidarabine—Hypotension—Methotrexate—ankylosing spondylitis	0.00213	0.00219	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Methotrexate—ankylosing spondylitis	0.00208	0.00214	CcSEcCtD
Vidarabine—Dizziness—Dexamethasone—ankylosing spondylitis	0.00207	0.00213	CcSEcCtD
Vidarabine—Dizziness—Betamethasone—ankylosing spondylitis	0.00207	0.00213	CcSEcCtD
Vidarabine—Nausea—Triamcinolone—ankylosing spondylitis	0.00205	0.00211	CcSEcCtD
Vidarabine—Paraesthesia—Methotrexate—ankylosing spondylitis	0.00205	0.00211	CcSEcCtD
Vidarabine—Nausea—Methylprednisolone—ankylosing spondylitis	0.00205	0.00211	CcSEcCtD
Vidarabine—Dyspnoea—Methotrexate—ankylosing spondylitis	0.00203	0.00209	CcSEcCtD
Vidarabine—Somnolence—Methotrexate—ankylosing spondylitis	0.00203	0.00209	CcSEcCtD
Vidarabine—Hypersensitivity—Prednisone—ankylosing spondylitis	0.00201	0.00207	CcSEcCtD
Vidarabine—Vomiting—Dexamethasone—ankylosing spondylitis	0.00199	0.00205	CcSEcCtD
Vidarabine—Vomiting—Betamethasone—ankylosing spondylitis	0.00199	0.00205	CcSEcCtD
Vidarabine—Rash—Dexamethasone—ankylosing spondylitis	0.00198	0.00203	CcSEcCtD
Vidarabine—Rash—Betamethasone—ankylosing spondylitis	0.00198	0.00203	CcSEcCtD
Vidarabine—Dermatitis—Dexamethasone—ankylosing spondylitis	0.00197	0.00203	CcSEcCtD
Vidarabine—Dermatitis—Betamethasone—ankylosing spondylitis	0.00197	0.00203	CcSEcCtD
Vidarabine—Headache—Betamethasone—ankylosing spondylitis	0.00196	0.00202	CcSEcCtD
Vidarabine—Headache—Dexamethasone—ankylosing spondylitis	0.00196	0.00202	CcSEcCtD
Vidarabine—Asthenia—Prednisone—ankylosing spondylitis	0.00196	0.00202	CcSEcCtD
Vidarabine—Pain—Methotrexate—ankylosing spondylitis	0.00195	0.00201	CcSEcCtD
Vidarabine—Nausea—Betamethasone—ankylosing spondylitis	0.00186	0.00192	CcSEcCtD
Vidarabine—Nausea—Dexamethasone—ankylosing spondylitis	0.00186	0.00192	CcSEcCtD
Vidarabine—Urticaria—Methotrexate—ankylosing spondylitis	0.00181	0.00186	CcSEcCtD
Vidarabine—Dizziness—Prednisone—ankylosing spondylitis	0.0018	0.00186	CcSEcCtD
Vidarabine—Vomiting—Prednisone—ankylosing spondylitis	0.00174	0.00179	CcSEcCtD
Vidarabine—Rash—Prednisone—ankylosing spondylitis	0.00172	0.00177	CcSEcCtD
Vidarabine—Dermatitis—Prednisone—ankylosing spondylitis	0.00172	0.00177	CcSEcCtD
Vidarabine—Headache—Prednisone—ankylosing spondylitis	0.00171	0.00176	CcSEcCtD
Vidarabine—Hypersensitivity—Methotrexate—ankylosing spondylitis	0.00168	0.00173	CcSEcCtD
Vidarabine—Asthenia—Methotrexate—ankylosing spondylitis	0.00164	0.00168	CcSEcCtD
Vidarabine—Nausea—Prednisone—ankylosing spondylitis	0.00162	0.00167	CcSEcCtD
Vidarabine—Dizziness—Methotrexate—ankylosing spondylitis	0.00151	0.00155	CcSEcCtD
Vidarabine—Vomiting—Methotrexate—ankylosing spondylitis	0.00145	0.00149	CcSEcCtD
Vidarabine—Rash—Methotrexate—ankylosing spondylitis	0.00144	0.00148	CcSEcCtD
Vidarabine—Dermatitis—Methotrexate—ankylosing spondylitis	0.00144	0.00148	CcSEcCtD
Vidarabine—Headache—Methotrexate—ankylosing spondylitis	0.00143	0.00147	CcSEcCtD
Vidarabine—Nausea—Methotrexate—ankylosing spondylitis	0.00135	0.00139	CcSEcCtD
